Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
17.11
-0.12 (-0.70%)
At close: Jun 27, 2025, 4:00 PM
17.25
+0.14 (0.82%)
After-hours: Jun 27, 2025, 7:59 PM EDT
Sarepta Therapeutics Market Cap
Sarepta Therapeutics has a market cap or net worth of $1.68 billion as of June 27, 2025. Its market cap has decreased by -85.34% in one year.
Market Cap
1.68B
Enterprise Value
2.52B
1-Year Change
-85.34%
Ranking
Category
Stock Price
$17.11
Market Cap Chart
Since December 1, 1998, Sarepta Therapeutics's market cap has increased from $58.40M to $1.68B, an increase of 2,779.32%. That is a compound annual growth rate of 13.47%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 27, 2025 | 1.68B | -85.52% |
| Dec 31, 2024 | 11.61B | 28.75% |
| Dec 29, 2023 | 9.02B | -20.70% |
| Dec 30, 2022 | 11.37B | 45.06% |
| Dec 31, 2021 | 7.84B | -41.72% |
| Dec 31, 2020 | 13.45B | 39.87% |
| Dec 31, 2019 | 9.62B | 31.90% |
| Dec 31, 2018 | 7.29B | 102.79% |
| Dec 29, 2017 | 3.60B | 140.16% |
| Dec 30, 2016 | 1.50B | -14.27% |
| Dec 31, 2015 | 1.75B | 192.17% |
| Dec 31, 2014 | 597.80M | -21.92% |
| Dec 31, 2013 | 765.60M | 16.58% |
| Dec 31, 2012 | 656.70M | 549.55% |
| Dec 30, 2011 | 101.10M | -57.54% |
| Dec 31, 2010 | 238.10M | 47.70% |
| Dec 31, 2009 | 161.20M | 244.44% |
| Dec 31, 2008 | 46.80M | -38.26% |
| Dec 31, 2007 | 75.80M | -54.99% |
| Dec 29, 2006 | 168.40M | 10.50% |
| Dec 30, 2005 | 152.40M | 79.51% |
| Dec 31, 2004 | 84.90M | -33.15% |
| Dec 31, 2003 | 127.00M | -3.93% |
| Dec 31, 2002 | 132.20M | -47.73% |
| Dec 31, 2001 | 252.90M | 148.18% |
View and export this data all the way back to 1998.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 696.15B |
| Johnson & Johnson | 366.71B |
| Novo Nordisk | 331.06B |
| AbbVie | 322.03B |
| UnitedHealth Group | 280.41B |
| Abbott Laboratories | 233.80B |
| Novartis AG | 227.75B |
| AstraZeneca | 220.36B |